Skip to main content
SpringerLink
Log in

Early Suppression of Striatal Cyclic GMP May Pre-Determine the Induction and Severity of Chronic Haloperidol-Induced Vacous Chewing Movements

  • Published:
Metabolic Brain Disease Aims and scope Submit manuscript

Abstract

Haloperidol persists in brain tissue long after discontinuation while haloperidol -induced tardive dyskinesia often worsens after withdrawal of the drug. The mechanism of haloperidol -associated tardive dyskinesia is unknown, although neurotoxic pathways are suspected. Nitric oxide (NO) synthase (NOS) inhibitors exacerbate haloperidol -induced catalepsy, while haloperidol itself is a potent neuronal NOS inhibitor in vitro. Since NO and cGMP are involved in striatal neural plasticity, this study investigates a possible relation between cGMP and extrapyramidal symptoms as early predictors of haloperidol -associated tardive dyskinesia. Sprague-Dawley rats were administered either water or oral haloperidol (0.25mg/kg/d po) for 17 weeks, followed by 3 weeks withdrawal. Saline (ip) or the nNOS/guanylate cyclase inhibitor, methylene blue (5mg/kg/d ip), were co-administered with haloperidol for the first three weeks of treatment. Vacous chewing movements (VCM's) were continuously monitored, followed by the determination of striatal cGMP and peripheral serum nitrogen oxide (NOx) levels. Chronic haloperidol engendered significant VCM's, with acute withdrawal associated with significantly reduced striatal cGMP levels as well as reduced serum NOx. Furthermore, suppressed cGMP levels were maintained and VCM's were significantly worse after early administration of methylene blue to the chronic haloperidol group. However, serum NOx was unchanged from control. We conclude that the central effects of chronic haloperidol on striatal NO-cGMP function persist for up to 3 weeks post-withdrawal. Moreover, suppression of striatal cGMP constitutes an early neuronal insult that determines the presence and intensity of haloperidol -associated motor dysfunction.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  • APA Task Force on Tardive Dyskinesia (1992). Tardive dyskinesia-a task force report of the American Psychiatric Association. Washington, DC: APA Press.

    Google Scholar 

  • Arancio, O., Kandel, E.R., and Hawkins, R.D. (1995). Activity-dependent long-term enhancement of transmitter release by synaptic 3′5′-cyclic GMP in cultured hippocampal neurons. Nature 376:74-80.

    Google Scholar 

  • Avent, K.M. Usuki, E., Eyles, D.W., Keeve, R., Van der Schyf, C.J., Castagnoli, N, and Pond, S.M. (1996). Haloperidol and its tetrahydropyridine derivative (HPTP) are metabolized to potentially neurotoxic pyridium species in the baboon. Life Sci. 59:1473-1482; 1996.

    Google Scholar 

  • Behl, C., Lezoualc'h, F., Widmann, M., Rupprecht, R., and Holsboer, F. (1996). Oxidative stress-resistant cells are protected against haloperidol toxicity. Brain Res. 717:193-195.

    Google Scholar 

  • Borda, T., Genaro, A.M., and Cremaschi, G. (1999). Haloperidol effect on intracellular signals system coupled to alpha-1 adrenergic receptor in rat cerebral cortex. Cell Signal 11:293-300.

    Google Scholar 

  • Calabresi, P., Gubellini, P., Centonze, D., Sancesario, G., Morello, M., and Giorgi M., Pisa (1999). A critical role for the nitric oxide/cGMP pathway in corticostriatal long-term depression. J. Neurosci. 19:2489-2499.

    Google Scholar 

  • Cohen, B.M., Tsuneizumi, T., Balsessarini, R.J., Campbell, A., and Babb, S. (1992). Differences between antipsychotic drugs in persistence of brain levels and behavioral effects. Psychopharmacol 108:338-344.

    Google Scholar 

  • Colasanti, M., and Suzuki, H. (2000). The dual personality of NO. Trends Pharmacol. Sci. 21:249-252.

    Google Scholar 

  • Cortas, N.K., and Wakid, N.W. (1990). Determination of inorganic nitrate in serum and urine by a kinetic cadmium-reduction method. Clin Chem 36:1440-1443.

    Google Scholar 

  • Del Bel, E.A., and Guimaraes, F.S. (2000). Sub-chronic inhibition of nitric oxide synthesis modifies haloperidol-induced catalepsy and the number of NADPH-diaphorase neurones in mice. Psychopharmacol 147:356-361.

    Google Scholar 

  • Del-Bel, E.A., Da Silva, C.A., and Guimaraes, F.S. (1998). Catalepsy induced by nitric oxide synthase inhibitors. Gen Pharmacol 30:245-248.

    Google Scholar 

  • Egan, M.F., Ferguson, J.N., and Hyde, T.M. (1995). Effects of chronic naloxone administration on vacous chewing movements and catalepsy in rats treated with long-term haloperidol decanoate. Brain Res. Bull. 38:355-363.

    Google Scholar 

  • Eroglu, L., and Caglayan, B. (1997). Anxiolytic and antidepressant properties of methylene blue in animal models. Pharmacol. Res. 36:381-385.

    Google Scholar 

  • Gibbon, C.J., and Swanepoel, C.R. (Eds) (1997). South African Medicines Formulary, 4th Edition, Medical Association of South Africa Publications, p371.

  • Gordge, M.P. (1998). How cytotoxic is nitric oxide? Exp. Nephrol. 6:12-16.

    Google Scholar 

  • Grimm, J.W., Kruzich, P.J., and See, R.E. (1998). Emergence of oral and locomotor activity in chronic haloperidol-treated rats following cortical N-methyl-D aspartate stimulation. Pharmacol. Biochem. Behav. 60:67-173.

    Google Scholar 

  • Guevara-Guzman, R., Emson, P.C., and Kendrick, K.M. (1994). Modulation of in vivo striatal transmitter release by nitric oxide and cyclic GMP. J. Neurochem. 62:807-810.

    Google Scholar 

  • Harvey, B.H., and Bester, A. (2000). Withdrawal-associated changes in peripheral nitrogen oxides and striatal cyclic GMP after chronic haloperidol treatment. Behav. Brain Res. 111:203-211.

    Google Scholar 

  • Harvey, B.H., Carstens, M.E., and Taljaard, J.J.F. (1994). Evidence that lithium induces a glutamate-nitric oxide-mediated response in rat brain. Neurochem Res. 19:469-474.

    Google Scholar 

  • Harvey,B.H., Stein, D.J., and Emsley, R.A. (1999). The new generation antipsychotics: Integrating the neuropathology and pharmacology of schizophrenia. S. Afr. Med. J. 89:661-672.

    Google Scholar 

  • Harvey, B.H. (1996). Affective disorders and nitric oxide: A role in pathways to relapse and refractoriness? Hum. Psychopharmacol. 11:309-319.

    Google Scholar 

  • Hirsch, E.C., and Hunot, S. (2000). Nitric oxide, glial cells and neuronal degeneration in parkinsonism. Trends Pharmacol. Sci. 21:163-165.

    Google Scholar 

  • Hu, J., Lee, J.H., and El-Fakahany, E. (1994). Inhibition of neuronal nitric oxide synthase by antipsychotic drugs. Psychopharmacol 114:161-166.

    Google Scholar 

  • Hubbard, J.W., Ganes, D., and Midha, K.K. (1987). Prolonger pharmacologic activity of neuroleptic drugs. Arch Gen. Psychiatry 44:99-100.

    Google Scholar 

  • Kanner, J., Harel, S., and Granit, R. (1992). Nitric oxide, an inhibitor of lipid peroxidation by lipoxygenase, cyclooxygenase and hemoglobin. Lipids 27:46-49.

    Google Scholar 

  • Kornhuber, J., Schultz, A., Wiltfang, J., Meineke, I., Gleiter, C.H., Zochling, R., Boissl, K.W., Leblhuber, F., and Riederer, P. (1999). Persistance of haloperidol in human brain tissue. Am. J. Psychiatry 156:885-890.

    Google Scholar 

  • Lipton, S.A., Choi, Y.B., Pan, Z.H., Lei, S.Z., Chen, H.S.V., Sucher, N.J., Loscalzo, J., Singel, D.J., and Stamler, J.S. (1993). A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds. Nature 364:626-632.

    Google Scholar 

  • Masaki, E., and Kondo, I. (1999). Methylene blue, a soluble guanylyl cyclase inhibitor reduces the sevoflurane minimal alveolar anaesthetic concentration and decreases brain cyclic GMP content in rats. Anaesthesia and Analgesia 89:484-489.

    Google Scholar 

  • Moore, P.K., and Handy, R.L.C. (1997). Selective inhibitors of neuronal nitric oxide synthase — is no NOS really good NOS for the nervous system? Tr. Pharmacol. Sci. 18:204-211.

    Google Scholar 

  • Nagase, S., Takemura, K., Ueda, A., Hirayama, A., Aoyagi, K., Kondoh, M., and Koyama, A. (1997). A novel non-enzymatic pathway for the generation of nitric oxide by reaction of hydrogen peroxide and D or L-arginine. Biochem. Biophys. Res. Comm. 233:150-153.

    Google Scholar 

  • Rosengarten, H., Schweitzer, J.W., and Friedhoff, A.J. (1999). The effect of novel antipsychotics in rat oral dyskinesia. Prog. Neuro-Psychopharmacol Biol. Psychiatry 23:1389-1404.

    Google Scholar 

  • SAS Institute (1988). SAS Procedures Guide Release, 6.03 Edition, SAS Institute Inc, NC, U.S.A.

    Google Scholar 

  • Suto, T., Losonczy, G., Qiu, C., Hill, C., Samsell, L., Ruby,J., Charon, N., Venuto, R., and Baylis, C. (1995). Acute changes in urinary excretion of nitrite and nitrate do not necessarily predict renal vascular NO production. Kidney Int. 48:1272-1277.

    Google Scholar 

  • Tsai, G., Goff, D.C., Chang, R.W., Flood, J., Baer, L., and Coyle, J.T. (1998). Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. Am. J. Psychiatry 155:1207-1213.

    Google Scholar 

  • Volke, V., Wegener, G., Vasar, E., and Rosenberg, R. (1999). Methylene blue inhibits hippocampal nitric oxide synthase in vivo. Brain Research 826:303-305

    Google Scholar 

  • Wink, D.A., Vodovotz, Y., Grisham, M.B., DeGraff, W., Cook, J.C., Pacelli, R., Krishna, M., and Mitchell, J.B. (1999). Antioxidant effects of nitric oxide. In: Methods in Enzymlogy 301:413-424.

    Google Scholar 

  • Yokoyama, H., Kasai, N., Ueda, Y., Niwa, R., Konaka, R., Mori, N., Tsuchihashi, N., Matsue, T., Ohya-Nishiguchi, H., and Kamada, H. (1998). In vivo analysis of hydrogen peroxide and lipid radicals in the striatum of rats under long-term administration of a neuroleptic. Free Rad. Biol. Med. 24:1056-1060.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. School of Pharmacy (Pharmacology), Faculty of Health Sciences, University of Potchefstroom, Potchefstroom, North-West Province, 2520, South Africa

    Ans-Mari Bester

  2. School of Pharmacy (Pharmacology), Faculty of Health Sciences, University of Potchefstroom, Potchefstroom, North-West Province, 2520, South Africa

    Brian H. Harvey

Authors
  1. Ans-Mari Bester
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Brian H. Harvey
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bester, AM., Harvey, B.H. Early Suppression of Striatal Cyclic GMP May Pre-Determine the Induction and Severity of Chronic Haloperidol-Induced Vacous Chewing Movements. Metab Brain Dis 15, 275–285 (2000). https://doi.org/10.1023/A:1011171124603

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1011171124603

Search

Navigation